Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-05-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
东海证券股份有限公司关于昆药集团股份有限公司变更部分募集资金投资项目的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Donghai Securities, the sponsor institution, regarding the change in the use of part of the funds raised by Kunming Pharmaceutical Group Co., Ltd. It discusses the original fundraising project, the proposed changes to the investment projects funded by the raised capital, detailed project descriptions, investment amounts, and approvals by the board and supervisory committee. The document references regulatory rules related to fundraising and securities issuance, and it includes detailed financial and project data. This is not a simple announcement or a brief summary but a comprehensive verification opinion on the change of fundraising investment projects, which aligns with a Capital/Financing Update (CAP) filing type. The document length (5378 characters) and content confirm it is a substantive report rather than a mere announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-05-22 Chinese
关于前次募集资金使用情况的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the usage of previously raised funds by Kunming Pharmaceutical Group Co., Ltd. It includes specifics about the amount raised, the timing, the balance, the investment projects funded, changes in project allocations, and the actual benefits realized from these investments. It references regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange, and includes detailed tables of fund usage and project performance. The document is not a full annual or interim financial report, nor is it a simple announcement of a report. It is a comprehensive disclosure about the use of capital raised from previous equity offerings, consistent with a capital/financing update. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2019-05-22 Chinese
关于公司公开发行可转换公司债券摊薄即期回报、采取填补措施及相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's public issuance of convertible bonds, including analysis of the impact on financial indicators, risk warnings, necessity and feasibility of the issuance, measures to mitigate dilution of immediate returns, and commitments from the board and controlling shareholders. It references regulatory guidelines from the China Securities Regulatory Commission and discusses capital raising activities. The content focuses on financing activities and capital structure changes rather than presenting a full financial report or earnings release. The document length is substantial (9368 characters) and contains detailed financial assumptions and measures related to the convertible bond issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2019-05-22 Chinese
关于召开2019年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about the convening of the 2019 first extraordinary general meeting of shareholders (临时股东大会) for Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. It does not contain financial statements or detailed financial analysis but rather serves as an official announcement to shareholders about the meeting and its agenda. The document length is 3422 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2019-05-22 Chinese
非经营性损益、净资产收益率、每股收益明细表的鉴证报告
Regulatory Filings
2019-05-22 Chinese
前次募集资金使用情况的鉴证报告
Regulatory Filings
2019-05-22 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.